Skip to main content

Table 2 Results of the cost-effectiveness analysis from Societal and NHIS Perspectives

From: Cost-effectiveness and budget impact of covering Burkitt lymphoma in children under Ghana’s National Health Insurance Scheme

Perspective

Strategy

Cost per patient

DALYs per patient

ICER (Incremental cost per incremental DALY averted)

Societal

Current practice

$9,558

23.33

− $219

NHIS-reimbursed treatment

$8,302

17.60

 

NHIS/health system

Current practice

$0

23.33

$113

NHIS-reimbursed treatment

$647

17.60